TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and complex or multivessel coronary disease (TCW): an international, multicentre, prospective, open-label, non-inferiority, randomised controlled trial

Autor:	Kedhi, Elvin, Hermanides, Renicus S, Dambrink, Jan-Henk E, Singh, Sandeep K, Ten Berg, Jurriën M, van Ginkel, DirkJan, Hudec, Martin, Amoroso, Giovanni, Amat-Santos, Ignacio J, Andreas, Martin, Campante Teles, Rui, Bonnet, Guillaume, Van Belle, Eric, Conradi, Lenard, van Garsse, Leen, Wojakowski, Wojtek, Voudris, Vassilis, Sacha, Jerzy, Cervinka, Pavel, Lipsic, Erik, Somi, Samer, Nombela-Franco, Luis, Postma, Sonja, Piayda, Kerstin, De Luca, Giuseppe, Kolkman, Evelien, Malinowski, Krzysztof P, Modine, Thomas
Zdroj:	The Lancet; December-January 2024, Vol. 404 Issue: 10471 p2593-2602, 10p
Abstrakt:	Patients with severe aortic stenosis present frequently (∼50%) with concomitant obstructive coronary artery disease. Current guidelines recommend combined surgical aortic valve replacement (SAVR) and coronary artery bypass grafting (CABG) as the preferred treatment. Transcatheter aortic valve implantation (TAVI) and fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) represent a valid treatment alternative. We aimed to test the non-inferiority of FFR-guided PCI plus TAVI versus SAVR plus CABG in patients with severe aortic stenosis and complex coronary artery disease.
Databáze:	Supplemental Index
Externí odkaz:	Zobrazit plný text záznamu